In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $7.00. The company’s shares closed last Friday at $1.52.
Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, Spero Therapeutics, and MoonLake Immunotherapeutics. According to TipRanks, Selvaraju has an average return of -5.4% and a 33.80% success rate on recommended stocks.
Currently, the analyst consensus on Spero Therapeutics is a Moderate Buy with an average price target of $7.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $3.18 and a one-year low of $0.80. Currently, Spero Therapeutics has an average volume of 355.5K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SPRO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Read More on SPRO:
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics price target raised to $7 from $6 at H.C. Wainwright
- Spero Therapeutics reports Q2 EPS (23c), consensus (34c)
- Spero Therapeutics (SPRO) Q2 Earnings Cheat Sheet
- Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
